Table 3.
Clinical features of circulating tumor cell (CTC)-positive patients grouped by CTC count detected by DC01 at first sampling time point before radiotherapy.
| CTCs Counts | Total # of Patients with CTC | Clinical Features in Detail | ||
|---|---|---|---|---|
| Clinical T Stage | PSA Value (ng/mL) | Gleason Score | ||
| 1 | 12 | 1 | 10.70 | 8 (4+4) |
| 1c | 51.44 | 8 (4+4) | ||
| 1c | 21.90 | 7 (3+4) | ||
| 1c | 14.01 | 10 (5+5) | ||
| 2 | 11.21 | 9 (4+5) | ||
| 2 | 27.70 | 8 (4+4) | ||
| 3a | 12.90 | 8 (4+4) | ||
| 3a | 2.90 | 8 (4+4) | ||
| 3a | 18.73 | 8 (4+4) | ||
| 3a | 10.50 | 8 (4+4) | ||
| 3b | 9.00 | 8 (4+4) | ||
| 3b | 65.00 | 8 (4+4) | ||
| 2 | 4 | 1c | 6.22 | 8 (4+4) |
| 1c | 5.62 | 10 (5+5) | ||
| 1c | 34.60 | 8 (4+4) | ||
| 1c | 17.70 | 8 (4+4) | ||
| 4 | 1 | 2 | 12.00 | 8 (4+4) |
| 5 | 1 | 2b | 4.92 | 8 (4+4) |
| 10 | 1 | 1c | 52.10 | 8 (4+4) |
| 15 | 2 | 1c | 10.12 | 9 (4+5) |
| 3a | 30.20 | 8 (4+4) | ||
#: number, PSA: prostate specific antigen.